Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.

Vollenberg R, Jouni R, Norris PAA, Burg-Roderfeld M, Cooper N, Rummel MJ, Bein G, Marini I, Bayat B, Burack R, Lazarus AH, Bakchoul T, Sachs UJ.

Haematologica. 2019 Jun;104(6):1237-1243. doi: 10.3324/haematol.2018.211086. Epub 2019 Mar 28.

2.

Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates.

Marini I, Aurich K, Jouni R, Nowak-Harnau S, Hartwich O, Greinacher A, Thiele T, Bakchoul T.

Haematologica. 2019 Jan;104(1):207-214. doi: 10.3324/haematol.2018.195057. Epub 2018 Aug 16.

3.

Platelet activation in the presence of neutral protamine Hagedorn insulin: a new feature of antibodies against protamine/heparin complexes.

Zöllner H, Jouni R, Panzer S, Khadour A, Janzen L, Wesche J, Ten Berg M, Schellong S, Heinken A, Greinacher A, Bakchoul T.

J Thromb Haemost. 2017 Jan;15(1):176-184. doi: 10.1111/jth.13547. Epub 2016 Nov 30.

4.

Protamine (heparin)-induced thrombocytopenia: a review of the serological and clinical features associated with anti-protamine/heparin antibodies.

Bakchoul T, Jouni R, Warkentin TE.

J Thromb Haemost. 2016 Sep;14(9):1685-95. doi: 10.1111/jth.13405. Epub 2016 Aug 29. Review.

5.

Assessment of human platelet survival in the NOD/SCID mouse model: technical considerations.

Fuhrmann J, Jouni R, Alex J, Zöllner H, Wesche J, Greinacher A, Bakchoul T.

Transfusion. 2016 Jun;56(6):1370-6. doi: 10.1111/trf.13602. Epub 2016 Apr 18.

PMID:
27086568
6.

Further insights into the anti-PF4/heparin IgM immune response.

Krauel K, Schulze A, Jouni R, Hackbarth C, Hietkamp B, Selleng S, Koster A, Jensch I, van der Linde J, Schwertz H, Bakchoul T, Hundt M, Greinacher A.

Thromb Haemost. 2016 Apr;115(4):752-61. doi: 10.1160/TH15-08-0654. Epub 2015 Oct 15.

PMID:
26467272
7.

Partially desulfated heparin modulates the interaction between anti-protamine/heparin antibodies and platelets.

Jouni R, Zöllner H, Khadour A, Wesche J, Grotevendt A, Brandt S, Delcea M, Krauel K, Schwertz H, Sachs UJ, Greinacher A, Bakchoul T.

Thromb Haemost. 2016 Jan;115(2):324-32. doi: 10.1160/TH15-07-0539. Epub 2015 Oct 1.

PMID:
26423467
8.

Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.

Baud M, Strano S, Dechartres A, Jouni R, Triponez F, Chouaid C, Forgez P, Damotte D, Roche N, Régnard JF, Alifano M.

J Thorac Cardiovasc Surg. 2013 May;145(5):1305-11. doi: 10.1016/j.jtcvs.2012.09.023. Epub 2012 Oct 13.

9.

Thoracoplasty in the current practice of thoracic surgery: a single-institution 10-year experience.

Stefani A, Jouni R, Alifano M, Bobbio A, Strano S, Magdeleinat P, Regnard JF.

Ann Thorac Surg. 2011 Jan;91(1):263-8. doi: 10.1016/j.athoracsur.2010.07.084.

PMID:
21172527
10.

Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients.

Stefani A, Alifano M, Bobbio A, Grigoroiu M, Jouni R, Magdeleinat P, Regnard JF.

J Thorac Cardiovasc Surg. 2010 Aug;140(2):356-63. doi: 10.1016/j.jtcvs.2010.02.018. Epub 2010 Apr 9.

Supplemental Content

Support Center